Infection and Drug Resistance

LETTER

1713

Effect of Intestinal Microbiota Transplantation on Intestinal Flora and Inflammatory Factor Levels in Patients with Ulcerative Colitis [Letter]

Indah Lestari Daeng Kanang 🝺

Department of Internal Medicine, Faculty of Medicine, Universitas Muslim Indonesia, Makassar, Indoensia

Correspondence: Indah Lestari Daeng Kanang, Department of Internal Medicine, Faculty of Medicine, Universitas Muslim Indonesia, Makassar, Indoensia, Email indahlestaridaeng.kanang@umi.ac.id

Dear editor

I have read the paper by Zhi Wang et al on the Effect of Intestinal Microbiota Transplantation on Intestinal Flora and Inflammatory Factor Levels in Patients with Ulcerative Colitis.¹ I congratulate the authors for providing updated information regarding the role of the gut microbiota in the treatment of patients suffering from Ulcerative Colitis. The findings in this study can be used as a consideration for the choice of therapy for Ulcerative Colitis patients in addition to giving anti-inflammatory drugs such as Dexamethasone because Microbiota Transplantation on Intestinal is still a new therapy in the world of health.²

A study conducted by Zhi Wang et al proved that intestinal microbiota transplantation can improve the condition of the gut microbiota in ulcerative colitis patients, reduce excessive inflammatory responses, and facilitate restoration of intestinal mucosal function without any significant side effects.¹ However, care should be taken in the selection. The right donor is recommended to do an examination of the donor's bacterial profile first.³ In addition, I also want to provide the latest information regarding conventional probiotics which can affect the nature of the microbiota in the human intestine, this therapy can be a prevention and treatment for patient ulcerative colitis that targets a deregulated immune response as well as intestinal dysbiosis as supported by a number of clinical trials. Probiotics help maintain remission for a longer time and improve the quality of life for ulcerative colitis patient.⁴

The study conducted by Zhi Wang et al used correspondents of patients diagnosed with ulcerative colitis who were divided into a control group that was given oral mesalamine and an intervention group that was given oral mesalamine plus intestinal microbiota transplantation.¹ The method used has been able to assess the effectiveness of intestinal microbiota transplantation, however I recommend adjunctive therapy such as administration of conventional probiotic strains with common approaches applied in disease management to modify gut microbiota, improve gut barrier integrity and function, and maintain a balanced immune response.⁴ In addition, intestinal microbiota transplantation can also help doctors predict the success of ulcerative colitis treatment.⁵

In conclusion, I agree that intestinal microbiota transplantation can efficiently improve the condition of the intestinal microbiota of ulcerative colitis patients, reduce the inflammatory response in the patient's body and assist in the restoration of the function of the intestinal mucosal layer and also act as a reservoir for potentially pathogenic organisms. The presence of disturbances in the intestinal microbiota can increase the risk of invasive infection from intestinal pathogens.¹ Therefore, a strategy to restore the composition of the intestinal microbiota is a potential strategy that should be of primary concern to reduce the risk of developing cases of ulcerative colitis.³ However, I also recommend giving conventional probiotic therapy, which can help maintain remission for a longer time and improve the quality of life of ulcerative colitis patients.⁴

© 2023 Kanang. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.phg work work and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://treativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (http://www.dovepress.com/terms.phg).

Disclosure

The author reports no conflicts of interest in this communication.

References

- 1. Wang Z, Yang L, Sun S. Effect of intestinal microbiota transplantation on intestinal flora and inflammatory factor levels in patients with ulcerative colitis. *Infect Drug Resist.* 2023;16:1183–1191. doi:10.2147/IDR.S394614
- 2. Dong K, Deng S-J, He B-Y, et al. Mucoadhesive nanoparticles enhance the therapeutic effect of dexamethasone on experimental ulcerative colitis by the local administration as an enema. *Drug Des Devel Ther.* 2023;17:191–207. doi:10.2147/dddt.s390274
- 3. Biazzo M, Deidda G. Fecal microbiota transplantation as new therapeutic avenue for human diseases. J Clin Med. 2022;11(14):4119. doi:10.3390/jcm11144119
- 4. Štofilová J, Kvaková M, Kamlárová A, Hijová E, Bertková I, Guľašová Z. Probiotic-based intervention in the treatment of ulcerative colitis: conventional and new approaches. *Biomedicines*. 2022;10(9):1–23. doi:10.3390/biomedicines10092236
- Ghani R, Mullish BH, Roberts LA, Davies FJ, Marchesi JR. The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases. *Gut Microbes*. 2022;14(1):1–21. doi:10.1080/19490976.2022.2038856

Dove Medical Press encourages responsible, free and frank academic debate. The contentTxt of the Infection and Drug Resistance 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Infection and Drug Resistance editors. While all reasonable steps have been taken to confirm the contentTxt of each letter, Dove Medical Press accepts no liability in respect of the contentTxt of any letter, nor is it responsible for the contentTxt and accuracy of any letter to the editor.

Infection and Drug Resistance

Dovepress

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/infection-and-drug-resistance-journal

https://doi.org/10.2147/IDR.\$412512